AbbVie announced the VIALE-C trial of venetoclax in combination with low-dose cytarabine versus LDAC in combination with placebo did not meet its primary endpoint of statistically significant improvement of overall survival for patients with acute myeloid leukemia who are ineligible for intensive chemotherapy at the time of the planned analysis.Treatment with the venetoclax combination showed a 25% reduction in the risk of death compared to LDAC with placebo. The venetoclax with LDAC arm also showed a median OS of 7.2 months vs. 4.1 months in the LDAC arm alone. A post-hoc analysis after an additional six months of follow up showed an increase in median OS of 8.4 months in the venetoclax plus LDAC arm and 4.1 months in the placebo plus LDAC arm.

Invitation Homes announced the cancellation of the company's roundtable discussion and webcast at Citi's 2020 Global Property CEO Conference, previously scheduled to take place on Tuesday, March 3, at 10:20 a.m. Eastern Time. Management no longer plans to attend the conference out of an abundance of caution amidst evolving uncertainty related to COVID-19.

Hudson Pacific Properties announced the cancellation of the company's presentation and webcast at Citi's 2020 Global Property CEO Conference, previously scheduled to take place on Tuesday, March 3, at 11:00 a.m. ET. Management no longer plans to attend the conference in light of a growing list of cancellations.

In an interview on CNBC's Mad Money, Clean Harbors CEO Alan McKim said, "We had a great fourth quarter and have a good year ahead of us." He noted that the company's environmental business is really strong and expects that trend to continue in 2020. McKim added that customers are buying into the company's sustainability efforts.

In a regulatory filing, Wolverine World Wide's president of Global Operations and Heritage Groups Michael Jeppesen disclosed the sale of 45,493 common shares of the company on February 27 at a price of $27.65 per share.

GlaxoSmithKline announced that the U.S. Food and Drug Administration has approved Advil Dual Action with Acetaminophen as an over-the-counter product for pain relief. The exclusive formula is now the first FDA-approved OTC combination of ibuprofen and acetaminophen in the United States and will be available over-the-counter nationwide in 2020. Franck Riot, Head of R&D, GSK Consumer Healthcare said: "For decades, many consumers have been using ibuprofen and acetaminophen to get the benefits of both active ingredients when safely treating their headaches, muscle aches, backaches, arthritis and other joint pain. Now Advil, the No. 1 selling OTC pain reliever, will offer US consumers the first-ever alternative option -- a single, fixed-dose combination pain reliever. As the world-leader in pain relief, Advil Dual Action and our recently FDA-approved Voltaren Arthritis Pain gel, demonstrates GSK's commitment to providing new safe, effective and convenient pain relief options for consumers."

Lockheed Martin was awarded a $141.66M modification to a previously awarded fixed-price-incentive-firm-target contract. This modification provides for the stand-up of organic level repair capabilities for the combat aircraft F-35 communications, navigation and information system. Work is expected to be completed by June 2024. FY19 aircraft procurement funds in the amount of $70.83M, FY19 aircraft procurement funds in the amount of $35.41M and FY19 aircraft procurement funds in the amount of $35.41M will be obligated at time of award, none of which will expire at the end of the current fiscal year. The Naval Air Systems Command is the contracting activity.

Bell-Boeing was awarded a $165.28M modification to a previously awarded fixed-price-incentive-firm-target, cost-plus-fixed-fee contract for the manufacture and delivery of two MV-22B variation in quantity aircraft for the Marine Corps and to provide funding for additional repairs in support of the Common Configuration-Readiness and Modernization Program. Work is expected completion by September 2023. FY20 aircraft procurement funds in the amount of $165.28M will be obligated at time of award, none of which will expire at the end of the current fiscal year. The Naval Air Systems Command is the contracting activity.

Northrop Grumman has been awarded a $262.28M firm-fixed price modification to a previously awarded contract for active electronically scanned array radars of Air Force F-16 aircraft. This modification is for the exercise of options to include 15 engineering, manufacturing and development and 90 production radars, as well as associated support equipment and spares. Work will be performed at Linthicum Heights, Maryland, and is expected to be completed by December 2022. The total cumulative face value of the contract is $553.45M. FY20 research and development funds in the amount of $34.18M; FY18 procurement funds in the amount of $88.2M and FY20 procurement funds in the amount of $197.96M are being obligated at the time of award. The Air Force Life Cycle Management Center is the contracting activity.

Vectrus was awarded a $121.78M modification to a contract for continued support of critical operation, maintenance and defense of Army communications. Work will be performed in Kuwait, with an estimated completion date of August 28. FY20 operations and maintenance funds in the amount of $121.78M were obligated at the time of the award. U.S. Army Contracting Command is the contracting activity.

Chesapeake Granite announced that it has received notification from the New York Stock Exchange of its determination to suspend trading of the trust's common units, effective immediately, and to initiate proceedings to delist the trust units. The determination to commence the delisting proceeding results from the trust's inability to satisfy the continued listing compliance standards set forth under Rule 802.01C of the NYSE listed company manual because the average closing price of the trust units fell below $1.00 over a 30 consecutive trading-day period, and the trust was unable to regain compliance with the applicable standards within a six-month cure period that concluded on February 28. As a result of the suspension, the trust expects that the trust units will begin trading on March 2 under the symbol (CHKR) on the OTC Pink Market, which is operated by OTC Markets Group.

Acasti Pharma announced that on February 28, 2020, it received written notification from the Nasdaq Listing Qualifications Department for failing to maintain a minimum bid price of U.S.$1.00 per share for the last 30 consecutive business days, as required by Nasdaq Listing Rule 5550a2 - bid price. The Nasdaq notification has no immediate effect on the listing of Acasti Pharma's shares. Under Nasdaq Listing Rule 5810c3A - compliance period, Acasti Pharma has 180 calendar days, or until August 26, 2020, to regain compliance. If at any time over this period the bid price of Acasti Pharma's shares closes at $1.00 per share or more for a minimum of ten consecutive business days, Nasdaq will provide written confirmation of compliance and the matter will be closed.